Abstract:
:Current treatments for brain cancer have, for the most part, equivocal survival benefit. However, clinical trials of new anticancer agents do not adequately assess potential clinical benefits for patient function other than survival and time to tumor progression. We evaluated 56 patients with recurrent brain tumors who were recruited on phase 1 and phase 2 clinical trials and given assessments of cognitive function, quality of life (QOL), and ability to perform activities of daily living (ADL) prior to receiving treatment and at intervals coinciding with MRI scans, generally monthly. Meaningful change on the cognitive and functional assessments was determined by the reliable change index. Cognitive or functional deterioration was then used as a time-dependent covariate in a Cox proportional hazards regression model with tumor progression, as defined by standard criteria, as the end point. Cognitive deterioration occurred 6 weeks prior to radiographic failure (median 7.4 weeks vs. 13.4 weeks). In contrast, median time for QOL to deteriorate was not achieved. Median time for instrumental ADL to decline was 43 weeks, long after tumor progression. For patients with brain cancer, brain function began to worsen before MRI evidence of tumor progression. QOL and ADL function were not strongly tied to cognitive decline or to time to tumor progression, suggesting that these measures may not be sufficiently sensitive to change in clinical trials of new anticancer agents, although they are important measures in terms of patient care. This study also demonstrates the feasibility of performing neurocognitive testing in this patient population. New drugs that slow the cognitive decline of brain tumor patients may be of clinical benefit regardless of the impact on overall survival.
journal_name
Neuro Oncoljournal_title
Neuro-oncologyauthors
Meyers CA,Hess KRdoi
10.1093/neuonc/5.2.89keywords:
subject
Has Abstractpub_date
2003-04-01 00:00:00pages
89-95issue
2eissn
1522-8517issn
1523-5866journal_volume
5pub_type
杂志文章相关文献
NEURO-ONCOLOGY文献大全abstract::Medulloblastoma (MB) is the most common pediatric brain cancer. Several important developmental pathways have been implicated in MB formation, but fewer therapeutic targets have been identified. To locate frequently overexpressed genes, we performed a comprehensive gene expression survey of MB. Our comparison of 20 pr...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1215/15228517-2008-038
更新日期:2008-10-01 00:00:00
abstract::To determine racial and ethnic differences in incidence and survival in patients with primary central nervous system lymphoma (PCNSL), NCI Surveillance, Epidemiology, and End Results (SEER) program data from 1992 to 2002 were queried. Data were substratified by age (20-49 years vs. 50 or above) and race (White, Black,...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1215/15228517-2008-103
更新日期:2009-06-01 00:00:00
abstract:BACKGROUND:Cisplatin-Induced Peripheral Neuropathy (CIPN) is a frequent serious dose-dependent adverse event that can determine dosage limitations for cancer treatment. CIPN severity correlates with the amount of platinum detected in sensory neurons of the dorsal root ganglia (DRG). However, the exact pathophysiology o...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/noaa151
更新日期:2020-06-29 00:00:00
abstract::Glutathione S-transferases (GSTs) are polymorphic enzymes that catalyze the glutathione conjugation of alkylating agents, platinum compounds, and free radicals formed by radiation used to treat medulloblastoma. We hypothesized that GST polymorphisms may be responsible, in part, for individual differences in toxicity a...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1215/15228517-2008-089
更新日期:2009-06-01 00:00:00
abstract::We have previously demonstrated that chordomas express activated platelet-derived growth factor receptor (PDGFRB) and that treatment with imatinib, which is capable of switching off the activation of various receptor tyrosine kinases (RTKs) including PDGFRB, benefits a number of patients. The aim of this study was to ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/noq003
更新日期:2010-08-01 00:00:00
abstract:BACKGROUND:Detection of glioma with MRI contrast agent is limited to cases in which the blood-brain barrier (BBB) is compromised as contrast agents cannot cross the BBB. Thus, an early-stage infiltrating tumor is not detectable. Interleukin-13 receptor alpha 2 (IL-13Rα2), which has been shown to be overexpressed in gli...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nov263
更新日期:2016-05-01 00:00:00
abstract:BACKGROUND:Ependymomas are rare CNS tumors. Previous studies describing the clinical course of ependymoma patients were restricted to small sample sizes, often with patients at a specific institution. METHODS:Clinically annotated ependymoma tissue samples from 19 institutions were centrally reviewed. Patients were all...
journal_title:Neuro-oncology
pub_type: 杂志文章,多中心研究
doi:10.1093/neuonc/nou162
更新日期:2015-03-01 00:00:00
abstract::This paper explicates the impact of tumor capillary permeability for glioma World Health Organization (WHO) grades II to IV on brain-penetrant drug entry and distribution within the tumor and the brain adjacent to tumor (leading edge). In addition, we consider the distribution of non-brain penetrant drugs and how, in ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/noy018
更新日期:2018-04-09 00:00:00
abstract:INTRODUCTION:Surgery is first-line therapy for glioblastoma, and there is evidence that gross total resection is associated with improved survival. Gross total resection, however, is not always possible, and relationships among extent (percent) of resection (EOR), residual volume (RV), and survival are unknown. The goa...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/not137
更新日期:2014-01-01 00:00:00
abstract::Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF) that has efficacy in recurrent malignant gliomas, particularly in combination with irinotecan. However, responses are rarely durable. Continuation of bevacizumab in combination with another chemotherapeutic agent may demon...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1215/15228517-2009-006
更新日期:2009-10-01 00:00:00
abstract::Although treatment of medulloblastoma has improved, at least 30% of patients with this tumor die of progressive disease. Unfortunately, many of the children who survive suffer long-term treatment-related morbidity. Previous studies have demonstrated the efficacy of using oncolytic viruses to eradicate brain tumors. Th...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/noq057
更新日期:2010-10-01 00:00:00
abstract::In order to compare in vivo metabolism between malignant gliomas and normal brain, (13)C magnetic resonance (MR) spectroscopic imaging data were acquired from rats with human glioblastoma xenografts (U-251 MG and U-87 MG) and normal rats, following injection of hyperpolarized [1-(13)C]-pyruvate. The median signal-to-n...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nop043
更新日期:2010-02-01 00:00:00
abstract::Blood vessels are composed of two interacting cell types. Endothelial cells form the inner lining of the vessel wall, and perivascular cells--referred to as pericytes, vascular smooth muscle cells or mural cells--envelop the surface of the vascular tube. Over the last decades, studies of blood vessels have concentrate...
journal_title:Neuro-oncology
pub_type: 杂志文章,评审
doi:10.1215/S1152851705000232
更新日期:2005-10-01 00:00:00
abstract::Transforming growth factor-beta (TGF-beta) is a proinvasive and immunosuppressive cytokine that plays a major role in the malignant phenotype of gliomas. One novel strategy of disabling TGF-beta activity in gliomas is to disrupt the signaling cascade at the level of the TGF-beta receptor I (TGF-betaRI) kinase, thus ab...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1215/15228517-2007-010
更新日期:2007-07-01 00:00:00
abstract::Tumor treating fields (TTFields) are low-intensity electric fields alternating at an intermediate frequency (200kHz), which have been demonstrated to block cell division and interfere with organelle assembly. This novel treatment modality has shown promise in a variety of tumor types. It has been evaluated in randomiz...
journal_title:Neuro-oncology
pub_type: 杂志文章,评审
doi:10.1093/neuonc/now182
更新日期:2016-10-01 00:00:00
abstract:BACKGROUND:Isocitrate dehydrogenase (IDH) mutation status has emerged as an important prognostic marker in gliomas. Currently, reliable IDH mutation determination requires invasive surgical procedures. The purpose of this study was to develop a highly accurate, MRI-based, voxelwise deep-learning IDH classification netw...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/noz199
更新日期:2020-03-05 00:00:00
abstract:BACKGROUND:Chemokine signaling may contribute to progression of low-grade gliomas (LGGs) by altering tumor behavior or impacting the tumor microenvironment. In this study, we investigated the role of CX3C chemokine receptor 1 (CX3CR1) signaling in malignant transformation of LGGs. METHODS:Ninety patients with LGGs wer...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/noaa075
更新日期:2020-10-14 00:00:00
abstract:BACKGROUND:Ofranergene obadenovec (VB-111) is an anticancer viral therapy that demonstrated in a phase II study a survival benefit for patients with recurrent glioblastoma (rGBM) who were primed with VB-111 monotherapy that was continued after progression with concomitant bevacizumab. METHODS:This pivotal phase III ra...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/noz232
更新日期:2020-05-15 00:00:00
abstract::Identification of the epidermal growth factor receptor variant III (EGFRvIII) mutation in glioblastoma has become increasingly relevant in the optimization of therapy. Traditionally, determination of tumor EGFRvIII-expression has relied on tissue-based diagnostics. Here, we assess the accuracy of magnetic resonance pe...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nos073
更新日期:2012-05-01 00:00:00
abstract::Stereotactic biopsy is often performed for diagnostic purposes before treating patients whose imaging studies highly suggest glioma. Indications cited for biopsy include diagnosis and/or the "inoperability" of the tumor. This study questions the routine use of stereotactic biopsy in the initial management of gliomas. ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/3.3.193
更新日期:2001-07-01 00:00:00
abstract:BACKGROUND:No reliable estimates are available on the incidence of brain metastasis (BM) in cancer patients. This information is valuable for planning patient care and developing measures that may prevent or decrease the likelihood of metastatic brain disease. METHODS:We report the first population-based analysis on B...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nou099
更新日期:2015-01-01 00:00:00
abstract:Background:Isocitrate dehydrogenase (IDH) mutations result in abnormal accumulation of 2-hydroxyglutarate (2HG) in gliomas that can be detected by MRS. We examined the diagnostic accuracy of 2HG single-voxel spectroscopy (SVS) and chemical shift imaging (CSI) in both newly diagnosed and posttreatment settings. Methods...
journal_title:Neuro-oncology
pub_type: 临床试验,杂志文章
doi:10.1093/neuonc/noy022
更新日期:2018-08-02 00:00:00
abstract::The vasculature of 24 primary CNS B-cell lymphomas that were not related to acquired immunodeficiency syndrome was systematically studied by electron microscopy. Seven low-grade astrocytic tumors were included for comparison. Classical electron microscopy features of apoptosis were found in lymphoma cells of 21 of 22 ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/1.2.89
更新日期:1999-04-01 00:00:00
abstract:BACKGROUND:We sought to determine the surgical treatment and functional outcome and identify the predictors of survival in a retrospective cohort of patients with spinal cord ependymoma using data collected from the Korea Spinal Oncology Research Group database. METHODS:The data regarding 88 patients who had been surg...
journal_title:Neuro-oncology
pub_type: 杂志文章,多中心研究
doi:10.1093/neuonc/not038
更新日期:2013-07-01 00:00:00
abstract::As immunotherapy assumes a central role in the management of many cancers, ongoing work is directed at understanding whether immune-based treatments will be successful in patients with glioblastoma (GBM). Despite several large studies conducted in the last several years, there remain no FDA-approved immunotherapies in...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/noaa154
更新日期:2020-10-14 00:00:00
abstract::High-grade gliomas release excitotoxic concentrations of glutamate, which has been shown to enhance tumor proliferation and migration. alpha-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) glutamate receptors are abundantly expressed at the invading edge of glioblastoma specimens, suggesting they may play an...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1215/15228517-2008-094
更新日期:2009-06-01 00:00:00
abstract:BACKGROUND:Available evidence on diet and glioma risk comes mainly from studies with retrospective collection of dietary data. To minimize possible differential dietary recall between those with and without glioma, we present findings from 3 large prospective studies. METHODS:Participants included 692 176 from the UK ...
journal_title:Neuro-oncology
pub_type: 杂志文章,meta分析
doi:10.1093/neuonc/noz013
更新日期:2019-07-11 00:00:00
abstract::The Atlas of Cancer Mortality in the United States, 1950-94 (Devesa et al.) published in 1999 by the National Institutes of Health suggests that there are elevated rates of brain and other nervous system cancer in the northwestern, north central, and southeastern parts of the country. Being descriptive in nature, the ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1215/S1152851703000450
更新日期:2004-07-01 00:00:00
abstract:INTRODUCTION:Overexpression of the Polycomb repressive complex 2 (PRC2) subunit Enhancer of Zeste 2 (EZH2) occurs in several malignancies, including prostate cancer, breast cancer, medulloblastoma, and glioblastoma multiforme. Recent evidence suggests that EZH2 may also have a role in rhabdoid tumors. Atypical teratoid...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nos285
更新日期:2013-02-01 00:00:00
abstract:BACKGROUND:Micro (mi)RNAs are key regulators of gene expression and offer themselves as biomarkers for cancer development and progression. Meningioma is one of the most frequent primary intracranial tumors. As of yet, there are limited data on the role of miRNAs in meningioma of different histological subtypes and the ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nov014
更新日期:2015-09-01 00:00:00